Work

P-099 Phase II trial of daratumumab, bortezomib, lenalidomide and dexamethasone in high-risk smoldering multiple myeloma

Year: 2023

Type: conference-abstract

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/s2152-2650(23)01717-2

Authors: Omar Nadeem, Robert Redd, Clifton Mo, Jacob Laubach, Paul G. Richardson, Julia Prescott, Marjorie Marto, Christine Davie, Caroline Ricciardi, Elizabeth Murphy, Meredith Bertoni, Dechen Choden, Sophie Magidson, Brian Sheehan, Hira Shrestha, Adam S. Sperling, Elizabeth K. O'Donnell, Irene M. Ghobrial

Institutions: Dana-Farber Cancer Institute, Harvard University, Massachusetts General Hospital

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4387003862

Cites:

Cited by: 1

Related to: 10